Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck

Cancer

Volumn 115, Issue 10, 2009, Pages 2138-2146

  Hainsworth, John D ^a   Spigel, David R ^a   Burris III, Howard A ^a   Markus, Tiffanie M ^a   Shipley, Dianna ^a   Kuzur, Michel ^b   Lunin, Scott ^b   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Florida Cancer Specialists   (United States)

Author keywords

Carboplatin; Chemoradiation; Docetaxel; Epidermal growth factor receptor inhibitors; Gefitinib; Head and neck cancer

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GEFITINIB;

ACNE; ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CATHETER INFECTION; CATHETER THROMBOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; ERYTHROCYTE TRANSFUSION; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE; RASH; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; SKIN BIOPSY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; QUINAZOLINES; REMISSION INDUCTION; TAXOIDS; TREATMENT OUTCOME;

EID: 65649133997     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24265     Document Type: Article

References (21)

1. Pignon JP, Bourbis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data - MACH-NC Collaborative Group, Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355:949-955.
2. Pignon JP, Baujat B, Bourhis J. Individual patient data meta-analyses in head and neck carcinoma: what have we learnt? Cancer Radiother. 2005;9:31-36.
3. Haddad R, Colevas AD, Tishler R, et al. Docetaxel, cisplatin and 5-fluorouracil based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2002;97:412-418.
4. Shin DM, Glisson BS, Khuri FR, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002;95:322-330.
5. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005;23:8636-8645.
6. Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst. 2004;96:1714-1717.
7. Hainsworth JD, Meluch AA, McClurkan S, et al. Paclitaxel, carboplatin and infusional 5-FU followed by radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Res Network. Cancer J. 2002;8:311-321.
8. Posner MR, Hershock D, Lelann L, et al. TAX 324: a phase III trial of TPF versus PF induction chemotherapy followed by chemoradiotherapy in locally advanced SCCNH. Paper presented at: 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6, 2006, Atlanta, Ga.
9. Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980-1987.
10. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177.
11. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
12. Calvert AH, Newell DR, Gumbrell LA. Carboplatin dosages prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85.
15. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646-8654.
16. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol. 2007;25:4880-4886.
17. Rueda A, Medina JA, Mesia R, et al. Gefitinib plus concomitant boost accelerated radiation (AFX-CB) and concurrent weekly cisplatin for locally advanced unresectable squamous cell head and neck carcinomas: a phase II study [abstract]. J Clin Oncol. 2007;25:306s. Abstract 6031.
18. Herchenhorn D, Dias FL, Pineda RM, et al. Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol. 2007;25:307s. Abstract 6033.
19. Ahmed SM, Cohen EE, Haraf DJ, et al. Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation followed by G adjuvant therapy for locally advanced head and neck cancer [abstract]. J Clin Oncol. 2007;25:306s. Abstract 6028.
20. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer. a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24:1072-1078.
21. Merlano MC, Numico G, Russi FG, et al. Cetuximab and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck: a phase II study [abstract]. J Clin Oncol. 2007;25:309s. Abstract 6043.